Launching at ATA: Eyenuk’s newest product - the EyeScreen™ Human + AI Diagnostic Service
Combining the high accuracy of AI disease detection with the accepted practice of human grading, the EyeScreen™ Service for diabetic retinopathy (DR) identifies cases of referable DR in any clinical setting with extremely high accuracy. This new service will be launching at this year’s ATA meeting in New Orleans.
The EyeScreen™ Service is designed to increase access to DR screening, reduce wait times, and improve patient compliance on receiving necessary screenings. Improved patient compliance and more screenings can lead to higher HEDIS scores and improved CMS Five-Star quality ratings.
By offering DR screening in their clinics, physicians can identify silently progressing DR sooner and begin intervention faster. This improves patient outcomes and reduces the incidenceof vision loss due to DR.Health care providers and systems will also likely save on the cost of treating severe DR by identifying and intervening sooner.
Come see how the EyeScreen™ Service can change the way you screen for DR at Booth #906.
How does it work?
The EyeScreen™ Service uses both a validated AI disease detection system and specialist human graders to assess retinal images. After these images are independently assessed by both the AI disease detection system and human graders separately, an ICD10 compliant report is sent to the physician. In the event that the AI and human graders disagree, the images are adjudicated by a highly experienced human expert.
Want to learn more about EyeScreen, EyeArt, or Eyenuk? Visit www.eyenuk.com
Eyenuk Inc., is a global artificial intelligence (AI) medical technology and services company and the leader in real-world AI Eye Screening™ for autonomous disease detection and AI Predictive Biomarkers™ for risk assessment and disease surveillance.
Eyenuk is on a mission to screen every eye in the world to ensure timely diagnosis of life- and vision-threatening diseases, including diabetic retinopathy, glaucoma, age-related macular degeneration, stroke risk, cardiovascular risk, and Alzheimer’s disease.